We are excited to be a vendor at BioTech Connect’s Krembil Discovery Tower event on September 18th in Toronto, Canada. It is home to the Krembil Research Institute, one of the world’s leading research centers focused on neurological disorders. Visit the Biocytogen booth to learn how our innovative neuroscience disease models can help advance your studies.
What is BioTech Connect?
BioTech Connect (BTC) is an event planning company for life science product exhibitions across Canada. Created by experienced scientists from academia and industry, their mission is to connect laboratory suppliers with researchers nationwide. These informative scientific trade shows are held at universities and hospital based research centers to promote the latest lab products and supplier service.
Event Overview
Date:September 18th, 2026
Venue: 60 Leonard Ave, Toronto, ON M5T 0S8, Canada
Event Schedule
For more information about the BTC vendor show, please visit their website here.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
